Januvia<sup>®</sup>: sitagliptin for type 2 diabetes
AbstractJanuvia® is available as a film-coated tablet that contains 25 mg, 50 mg and 100 mg of sitagliptin-free base, respectively. As monotherapy, it is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus. It is also indicated to increase glycaemic control in patients with type 2 diabetes mellitus, in combination with metformin or a peroxisome proliferator-activated receptor gamma (PPARγ)-agonist, e.g. a thiazolidinedione, when diet and exercise, together with the single agent, do not provide adequate glycaemic control.1
New Product Focus
By submitting manuscripts to SAPJ, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in SAPJ for educational and research purposes without obtaining permission.